NovoCure Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2021	FY 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '21 Dec 31, 2021	Dec '18 Dec 31, 2018
Revenue	655.35	605.22	509.34	535.03	248.07
Revenue Growth (YoY)	8.28%	18.82%	-4.80%	115.68%	2294.72%
Cost of Revenue	166.88	137.18	128.28	114.88	80.05
Gross Profit	488.47	468.04	381.06	420.15	168.02
Selling, General & Admin	417.73	428.89	390.87	263.18	151.12
Research & Development	224.54	209.65	223.06	201.3	50.57
Total Operating Expenses	642.27	638.54	613.93	464.49	201.69
Operating Income	-153.8	-170.5	-232.87	-44.33	-33.67
Total Non-Operating Income (Expense)	17.55	39.33	41.13	-7.74	12.27
Pretax Income	-136.25	-131.16	-191.74	-52.08	-45.94
Provision for Income Taxes	0.02	-37.47	-15.3	-6.28	-17.62
Net Income	-136.23	-168.63	-207.04	-58.35	-63.56
Net Income to Common	-136.23	-168.63	-207.04	-58.35	-63.56
Shares Outstanding (Basic)	111	108	106	104	93
Shares Outstanding (Diluted)	111	108	106	104	93
Shares Change (YoY)	3.37%	1.36%	1.90%	11.68%	686.22%
EPS (Basic)	-1.22	-1.56	-1.95	-0.60	-0.68
EPS (Diluted)	-1.22	-1.56	-1.95	-0.60	-0.68
Free Cash Flow	-75.68	-69.22	-100.43	58.59	-8.58
Free Cash Flow Per Share	-0.68	-0.64	-0.94	0.56	-0.09
Gross Margin	74.54%	77.33%	74.81%	78.53%	67.73%
Operating Margin	-23.47%	-28.17%	-45.72%	-8.29%	-13.57%
Profit Margin	-20.79%	-27.86%	-40.65%	-10.91%	-25.62%
FCF Margin	-11.55%	-11.44%	-19.72%	10.95%	-3.46%
EBITDA	-139.15	-159.26	-221.9	-34.08	-24.67
EBITDA Margin	-21.23%	-26.31%	-43.57%	-6.37%	-9.94%
EBIT	-153.8	-170.5	-232.87	-44.33	-33.67
EBIT Margin	-23.47%	-28.17%	-45.72%	-8.29%	-13.57%
Effective Tax Rate	-0.02%	28.56%	7.98%	12.05%	38.35%

Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q